Macitentan (ACT-064992), a Tissue-Targeting Endothelin Receptor Antagonist, Enhances Therapeutic Efficacy of Paclitaxel by Modulating Survival Pathways in Orthotopic Models of Metastatic Human Ovarian Cancer

Potential treatments for ovarian cancers that have become resistant to standard chemotherapies include modulators of tumor cell survival, such as endothelin receptor (ETR) antagonist. We investigated the therapeutic efficacy of the dual ETR antagonist, macitentan, on human ovarian cancer cells, SKOV...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kim, Sun-Jin, Kim, Jang Seong, Kim, Seung Wook, Brantley, Emily, Yun, Seok Joong, He, Junqin, Maya, Marva, Zhang, Fahao, Wu, Qiuyu, Lehembre, François, Regenass, Urs, Fidler, Isaiah J
Formato: Artigo
Idioma:Inglês
Publicado: Neoplasia Press Inc. 2011
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3033595/
https://ncbi.nlm.nih.gov/pubmed/21403842
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares